On this special episode of JHLT: The Podcast, the Digital Media Editors take a look back at the exciting science that was on display at ISHLT2025, the ISHLT 45th Annual Meeting & Scientific Sessions.

Topics include:

• Telomere biology disorders and lung transplantation
• The meeting's special focus on cardiogenic shock
• The apixiVAD trial exploring low dose apixaban in HeartMate 3 LVADs
• Myocardial recovery on durable LVADs

For the latest studies from JHLT, visit jhltonline.org/current, or, if you’re an ISHLT member, access your Journal membership at ishlt.org/jhlt. Full-text abstracts of the meeting can also be found at the JHLT website.

Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Peter Cho and senior author Abbas Ardehali, MD, to discuss the paper, “Severe primary graft dysfunction in heart transplant recipients using donor hearts after circulatory death: a United States Experience.”

Peter is a third year medical student at Drexel University, and Dr. Ardehali is professor of surgery and medicine and the Director of the Heart, Lung, and Heart-Lung Transplant programs at UCLA.

The episode explores:

• The study's findings regarding an increased incidence of severe PGD at 24 hours post-transplant in DCD over DBD recipients
• What risks weren't changed in DCD recipients—suggesting that DCD PGD is likely to be transient, and may have a different phenotype
• How NRP may impact the outcomes
• Mitigating the risk of PGD

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you’re an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Tune in again later this month for the Digital Media Editors’ findings and observations from the ISHLT2025 Annual Meeting in Boston.

Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Returning for a second study this month, the JHLT Digital Media Editors invite first author Charlotte Van Edom to discuss the paper, “Apixaban plasma levels in patients with HeartMate 3 support.”

As a cardiologist in training and a PhD candidate at the University Hospitals Leuven in Belgium, Van Edom’s work focuses on hemocompatibility and mechanical circulatory support, covering both short-term and long-term support.

The episode explores:

• The evolution of the use and understanding of direct oral anticoagulants (DOACs) during LVAD support, including the increased focus on Factor Xa inhibitors
• Encouraging findings from the study and what clinical practices might need to change if introducing apixaban
• Additional studies exploring DOACs in LVAD patients

For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you’re an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.

Treat or research pulmonary vascular diseases? Check out the first April episode for a study on sotatercept in PAH patients.

Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.